PolyPid (NASDAQ:PYPD) Issues Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) posted its quarterly earnings data on Wednesday. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23), Zacks reports.

PolyPid Trading Down 0.3 %

PYPD stock traded down $0.01 during midday trading on Wednesday, reaching $2.88. 3,177 shares of the company’s stock traded hands, compared to its average volume of 22,427. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. PolyPid has a fifty-two week low of $2.37 and a fifty-two week high of $7.00. The business has a 50-day moving average price of $3.02 and a two-hundred day moving average price of $3.32. The company has a market capitalization of $29.35 million, a P/E ratio of -0.37 and a beta of 1.32.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PYPD shares. RODMAN&RENSHAW upgraded shares of PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of PolyPid in a research note on Tuesday, January 28th. They set a “buy” rating and a $13.00 price objective for the company. Craig Hallum began coverage on PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright reduced their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 26th.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.